Neurocrine Biosciences
NBIX
$165.11
+6.63%
Neurocrine Biosciences Inc is a biopharmaceutical company focused on developing and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders, with key products addressing conditions like tardive dyskinesia and Huntington's disease chorea. The company has established itself as a leader in central nervous system and endocrine therapeutics, leveraging a portfolio of approved drugs and a robust clinical pipeline. The current investor narrative is dominated by strategic moves to bolster its long-term pipeline, such as the recent acquisition of Soleno Therapeutics to enter the high-growth rare disease market, juxtaposed with near-term stock volatility stemming from conservative sales guidance for its flagship product, Ingrezza, which has sparked debate about near-term execution versus long-term growth prospects.…
NBIX
Neurocrine Biosciences
$165.11
Related headlines
Investment Opinion: Should I buy NBIX Today?
Rating & Thesis: Hold. Neurocrine Biosciences presents a compelling long-term growth story but is currently fairly valued after a powerful rally, requiring flawless execution to justify further near-term upside. The unanimous bullish analyst sentiment and implied 130%+ earnings growth support the long-term thesis, but near-term risks are elevated.
Supporting Evidence: The valuation is in transition: a trailing P/E of 29.5x is at a premium, but the forward P/E of 12.5x would be a discount if $14.88 EPS is achieved. Revenue growth remains robust at 28.3% YoY, and profitability is strong with net margin expansion to 19.1%. The company's financial health is exceptional, with a debt-to-equity of 0.13 and TTM FCF of $748.7M funding its growth. The stock's 20.6% one-month surge has likely priced in near-term optimism.
Risks & Conditions: The two biggest risks are a failure to meet the high forward EPS estimates and another guidance miss for Ingrezza. This Hold rating would upgrade to a Buy if the stock pulls back to the $140-$145 range (offering a better entry) or if Q3 2026 earnings confirm the path to $14+ EPS. It would downgrade to Sell if revenue growth decelerates below 20% or if net income margins contract sequentially. The stock is currently fairly valued relative to its near-term growth prospects but carries a premium on trailing earnings.
Sign up to view all
NBIX 12-Month Price Forecast
The investment thesis hinges on a dramatic earnings inflection. The company's stellar fundamentals—98% gross margins, strong FCF, and a clean balance sheet—provide a solid foundation. However, the recent surge has priced in much of the near-term optimism, leaving limited margin for error. The wide dispersion in analyst forecasts underscores the uncertainty. The stance is neutral because the risk/reward appears balanced at the current price; the substantial upside in the bull case is countered by the stock's vulnerability to any stumble in execution. Upgrading to bullish would require a pullback to a more attractive entry point or concrete evidence that forward EPS will exceed $15. Downgrading to bearish would be triggered by a breakdown below key support at $140.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Neurocrine Biosciences's 12-month outlook, with a consensus price target around $214.64 and implied upside of +30.0% versus the current price.
Average Target
$214.64
13 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
13
covering this stock
Price Range
$132 - $215
Analyst target range
The stock is covered by 13 analysts, and the institutional sentiment is overwhelmingly bullish, as evidenced by a series of recent 'Buy' or 'Overweight' ratings from firms including JP Morgan, Citigroup, RBC Capital, and Wells Fargo, with no downgrades following the February guidance disappointment. While a precise consensus target price is not provided in the data, the high level of coverage and consistent bullish stance implies strong institutional support and an expectation that the recent acquisition and pipeline progress will drive long-term value, overshadowing near-term guidance concerns. The target price range, inferred from estimated revenue and EPS ranges, is wide, with estimated revenue for the forecast period spanning from $4.79 billion to $6.20 billion and EPS from $12.57 to $17.60. This wide dispersion signals significant uncertainty among analysts regarding the exact growth trajectory and the financial impact of the Soleno acquisition. The high-end targets likely assume successful integration, strong pipeline readouts, and market expansion for Ingrezza, while the low-end targets may factor in competitive pressures or slower-than-expected adoption of new therapies.
Bulls vs Bears: NBIX Investment Factors
The evidence currently favors the bull case, driven by a powerful combination of accelerating forward earnings expectations, a pristine balance sheet, and strong technical momentum reversing prior negative sentiment. However, the bear case presents credible near-term risks centered on valuation and execution. The single most important tension in the investment debate is whether the company can deliver on the massive earnings growth implied by its forward P/E of 12.5x. Resolution depends on successful integration of the Soleno acquisition and sustained commercial execution for Ingrezza without further guidance missteps. Failure on either front could trigger significant multiple compression given the elevated trailing valuation.
Bullish
- Exceptional Forward Earnings Growth: The forward P/E of 12.46x implies over 130% earnings growth from the trailing EPS of $1.54 to the consensus estimate of $14.88. This dramatic re-rating reflects high market confidence in the company's profitability trajectory following strategic moves like the Soleno acquisition.
- Fortress Balance Sheet & Strong Cash Flow: With a debt-to-equity ratio of 0.13 and a current ratio of 3.39, the company has minimal leverage and high liquidity. It generates substantial internal cash, evidenced by TTM free cash flow of $748.7 million, providing ample resources to fund growth and acquisitions without financial strain.
- Powerful Technical Momentum & Reversal: The stock has surged 20.63% over the past month, decisively reversing a -20.9% drawdown from February. Trading at 97.5% of its 52-week high ($162.39), it shows strong institutional buying and relative strength of 14.32 versus the market, signaling a successful sentiment shift.
- Robust Revenue Growth & High Margins: Q4 2025 revenue grew 28.33% YoY to $805.5 million, driven by product sales. The company maintains exceptional profitability with a gross margin of 97.82% and a net income margin that expanded to 19.08% in Q4 2025, demonstrating operating leverage.
Bearish
- Elevated Valuation & High Execution Risk: The trailing P/E of 29.49x is above its recent historical average (e.g., 22.95x at end of Q4 2025), indicating the stock is pricing in significant optimism. Trading near its 52-week high, it is vulnerable to any disappointment in growth or integration of the Soleno acquisition.
- Near-Term Guidance Disappointment & Volatility: The stock fell over 10% in February on conservative 2026 guidance for flagship product Ingrezza, highlighting dependence on a single product and sensitivity to quarterly execution. This event caused a -20.9% maximum drawdown, demonstrating near-term volatility risk.
- Wide Analyst Forecast Dispersion: Analyst EPS estimates range widely from $12.57 to $17.60, and revenue forecasts span from $4.79B to $6.20B. This significant uncertainty reflects debate over the growth trajectory and financial impact of the Soleno acquisition, complicating valuation.
- Revenue Concentration & Quarterly Lumpiness: Product revenue constituted $798.3M of the total $805.5M in Q4, showing heavy reliance on commercialized therapies. Furthermore, the net income margin dipped from 26.36% in Q3 to 19.08% in Q4, indicating earnings volatility from R&D and operating expense timing.
NBIX Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 28.01% one-year price change, but is currently consolidating near the upper end of its 52-week range. With a current price of $158.30, it is trading at approximately 97.5% of its 52-week high of $162.39, indicating strong momentum but also potential for near-term resistance and overextension. Recent short-term momentum has been exceptionally strong and accelerating, with a 20.63% gain over the past month and a 19.70% gain over the past three months, significantly outpacing the broader market's 6.31% and 10.28% returns over the same periods, respectively, suggesting a powerful bullish impulse likely driven by recent corporate actions. Key technical support is anchored at the 52-week low of $121.42, while immediate resistance sits at the 52-week high of $162.39; a decisive breakout above this level would signal a continuation of the powerful uptrend, whereas a failure could lead to a consolidation phase. The stock exhibits low systematic risk with a beta of 0.336, meaning it is approximately 66% less volatile than the S&P 500, which is atypical for a biotech stock and suggests its price movements are more idiosyncratic, driven by company-specific news like the Soleno acquisition and quarterly guidance rather than broader market swings. The stock's recent price action shows a sharp recovery from a significant drawdown, with a maximum drawdown of -20.9% during the provided period, which aligns with the February sell-off on disappointing guidance. The subsequent powerful rally of over 20% in one month, coupled with a relative strength of 14.32 versus the market, indicates strong institutional buying and a successful reversal of that negative sentiment, setting the stage for a test of all-time highs.
Beta
0.34
0.34x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$122-$166
Price range past year
Annual Return
+32.1%
Cumulative gain past year
| Period | NBIX Return | S&P 500 |
|---|---|---|
| 1m | +23.2% | +5.0% |
| 3m | +27.4% | +10.7% |
| 6m | +6.2% | +10.0% |
| 1y | +32.1% | +26.5% |
| ytd | +17.4% | +10.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NBIX Fundamental Analysis
Revenue growth remains robust but shows some quarterly volatility; the most recent Q4 2025 revenue was $805.5 million, representing a 28.33% year-over-year increase, though this marks a deceleration from the 29.7% sequential growth seen in Q3. The multi-quarter trend reveals strong expansion from $572.6 million in Q1 2025 to the Q4 level, driven almost entirely by product revenue, which constituted $798.3 million of the total, indicating the company's commercial execution on its core therapies is the primary growth engine, while collaboration revenue is minimal at $7.2 million. The company is solidly profitable, with Q4 2025 net income of $153.7 million and an exceptionally high gross margin of 97.82%, which is typical for a successful biopharma with proprietary drugs. Profitability has improved significantly year-over-year, as the net income margin expanded from 16.43% in Q4 2024 to 19.08% in Q4 2025, demonstrating operating leverage; however, margins can be lumpy quarter-to-quarter, as seen in the dip from a 26.36% net margin in Q3 2025, reflecting the impact of R&D investments and other operating expenses. The balance sheet is exceptionally healthy, with a strong current ratio of 3.39 and a very low debt-to-equity ratio of 0.128, indicating minimal financial leverage and ample liquidity. The company generates substantial cash internally, with trailing twelve-month free cash flow of $748.7 million, providing ample resources to fund its growth initiatives and the recent Soleno acquisition without straining its balance sheet; this financial fortress is further underscored by a return on equity of 14.71%, which signifies efficient use of shareholder capital.
Quarterly Revenue
$805500000.0B
2025-12
Revenue YoY Growth
+0.28%
YoY Comparison
Gross Margin
+0.97%
Latest Quarter
Free Cash Flow
$748700000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NBIX Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 29.49x, while the forward PE is significantly lower at 12.46x, indicating the market expects a substantial near-term earnings growth of over 130%, which aligns with analyst EPS estimates rising from $1.54 to an average of $14.88. The large gap between trailing and forward multiples reflects high confidence in the company's profitability trajectory post its recent investments and pipeline advancements. Compared to typical biotech or specialty pharma peers, a trailing PE of 29.5x is at a moderate premium, but the forward multiple of 12.5x would represent a significant discount if earnings materialize as forecasted. The stock's Price-to-Sales ratio of 4.93x and EV/Sales of 4.79x provide additional context, suggesting the market is valuing the company at just under 5x sales, a multiple that could be justified by its high margins and growth profile, especially when considering the gross margin of 98.18% and operating margin of 21.64%. Historically, the stock's own valuation has fluctuated; the current trailing PE of 29.49x is above its recent quarterly historical average seen in the data (e.g., 22.95x at end of Q4 2025, 16.65x at end of Q3 2025), suggesting the market is currently pricing in more optimistic expectations, likely tied to the strategic acquisition and long-term pipeline potential. Trading near the higher end of its own historical PE band indicates that execution risk is elevated, and the stock is vulnerable to any disappointments in growth or integration of new assets.
PE
29.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -277x~349x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Neurocrine's primary financial risk is not leverage or liquidity—its balance sheet is a fortress—but rather earnings volatility and product concentration. Net income margin fluctuated from 26.4% in Q3 2025 to 19.1% in Q4, reflecting lumpy R&D investments. Revenue is heavily concentrated in product sales ($798.3M of $805.5M in Q4), with Ingrezza as the flagship. Any slowdown in its growth or pricing pressure would directly impact the top line, and the company's elevated trailing P/E of 29.5x leaves little room for error.
Market & Competitive Risks: The stock trades at a premium to its own recent historical P/E average, creating valuation compression risk if growth decelerates. Its low beta of 0.336 suggests idiosyncratic, news-driven moves, but this also means it may not benefit from broader market rallies. The recent Soleno acquisition enters the competitive rare disease market, where integration challenges and clinical trial outcomes for new pipeline assets pose significant external threats. Furthermore, the wide dispersion in analyst targets signals high uncertainty, making the stock susceptible to sharp re-ratings on data readouts.
Worst-Case Scenario: The most damaging scenario would involve a double disappointment: Ingrezza sales missing already conservative guidance coupled with a clinical setback or integration failure from the Soleno acquisition. This could trigger a wave of analyst downgrades and a derating of the forward multiple. The realistic downside could see the stock retreat to its 52-week low of $121.42, representing a -23% decline from the current price of $158.30. The February sell-off, which saw a -20.9% drawdown on guidance alone, provides a recent precedent for such a move.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to deliver on the forward EPS of $14.88, which the 12.5x P/E is predicated on, could cause severe multiple compression. 2) Product Concentration: Heavy reliance on Ingrezza sales, which caused a 10%+ stock drop in February on conservative guidance. 3) Integration Risk: Challenges in integrating the Soleno acquisition or setbacks in its rare disease pipeline. 4) Valuation Risk: The stock trades at 97.5% of its 52-week high after a sharp rally, increasing vulnerability to profit-taking. The low beta of 0.336 means these are largely company-specific, not market, risks.
The 12-month forecast centers on a base case target range of $155 to $175 (55% probability), implying modest upside from $158.30. This assumes the company meets its guidance and forward EPS consensus of $14.88. The bull case (30% probability) targets $185 to $210, driven by earnings beats and successful pipeline catalysts. The bear case (15% probability) sees a retreat to $121 to $140, triggered by commercial disappointments or integration issues. The most likely scenario is consolidation with a slight upward bias, as the stock digests its recent gains and the market awaits proof of the earnings inflection.
NBIX's valuation presents a dual picture, making it fairly valued on balance. On a trailing basis, its P/E of 29.5x is above its own recent historical average and at a premium to many peers, suggesting it is fully valued or slightly overvalued based on current earnings. However, the forward P/E of 12.5x, based on expected EPS growth of over 130%, would be considered undervalued for a profitable company with 98% gross margins if those estimates are met. The market is currently paying a fair price that embeds high expectations for flawless execution over the next 12-18 months.
NBIX is a good stock for investors seeking profitable growth in the biopharma sector, but timing is crucial. The stock has surged 20.6% in the past month and trades near its 52-week high, limiting near-term upside. The forward P/E of 12.5x is attractive if the company hits its $14.88 EPS target, representing significant growth. However, the elevated trailing P/E of 29.5x and recent history of guidance-related volatility (-20.9% drawdown in February) mean the risk of a pullback is real. It is a good buy for long-term holders on a dip towards $140-$145, but less compelling for short-term traders at current levels.
NBIX is more suitable for a long-term investment horizon of 3-5 years. While it has low market correlation (beta 0.336), its price is driven by company-specific clinical and commercial milestones, which can cause short-term volatility, as seen in the 20.9% drawdown earlier this year. The investment thesis is based on multi-year earnings growth from its pipeline and acquisitions, not short-term trading dynamics. The lack of a dividend also makes it purely a capital appreciation story. A minimum holding period of 18-24 months is suggested to allow time for the forward earnings story to play out and to ride through potential quarterly volatility.